Patents by Inventor Julian F. Bond
Julian F. Bond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230227418Abstract: The invention relates to compounds that inhibit DUBs, particularly USP9X. The invention also includes methods of inhibiting DUBs, including USP9X, and methods of treating cancers.Type: ApplicationFiled: January 10, 2023Publication date: July 20, 2023Inventors: Richard Martinelli, Julian F. Bond
-
Patent number: 11691945Abstract: The invention relates to compounds that inhibit DUBs, particularly USP9X. The invention also includes methods of inhibiting DUBs, including USP9X, and methods of treating cancers.Type: GrantFiled: November 16, 2022Date of Patent: July 4, 2023Assignee: ProDeg, LLCInventors: Richard Martinelli, Julian F. Bond
-
Publication number: 20230150925Abstract: The invention relates to compounds that inhibit DUBs, particularly USP9X. The invention also includes methods of inhibiting DUBs, including USP9X, and methods of treating cancers.Type: ApplicationFiled: November 16, 2022Publication date: May 18, 2023Inventors: Richard Martinelli, Julian F. Bond
-
Patent number: 8540999Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.Type: GrantFiled: August 30, 2004Date of Patent: September 24, 2013Assignee: Merck Patent GmbHInventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-Chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
-
Patent number: 8338565Abstract: Disclosed herein are macrocyclic compounds and methods for their synthesis and use. In particular, macrocyclic compounds are disclosed that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.Type: GrantFiled: August 20, 2009Date of Patent: December 25, 2012Assignee: Ensemble Therapeutics CorporationInventors: Jinbo Lee, Julian F. Bond, Nicholas Terrett, Frank G. Favaloro, Jr., Daniel Wang, Timothy F. Briggs, Benjamin Adam Seigal, Wei-Chuan Sun, Stephen P. Hale
-
Publication number: 20100152099Abstract: The invention provides macrocyclic compounds and methods for their synthesis and use. In particular, the invention provides macrocyclic compounds that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.Type: ApplicationFiled: August 20, 2009Publication date: June 17, 2010Inventors: Jinbo Lee, Julian F. Bond, Nicholas Terrett, Frank G. Favaloro, JR., Daniel Wang, Timothy F. Briggs, Benjamin A. Seigal, Wei-Chuan Sun, Stephen P. Hale
-
Patent number: 7482008Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.Type: GrantFiled: September 15, 2000Date of Patent: January 27, 2009Assignee: Merck Patent GmbHInventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern, Julian F. Bond, Andrew W. Brauer, Malcolm Morville, Thomas J. Briner, Ze'ev Shaked
-
Patent number: 7211408Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: GrantFiled: June 16, 2003Date of Patent: May 1, 2007Assignee: Merck Patent GmbHInventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
-
Patent number: 6982326Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.Type: GrantFiled: January 29, 1999Date of Patent: January 3, 2006Assignee: ImmuLogic Pharmaceutical CorporationInventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
-
Publication number: 20040057959Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: ApplicationFiled: June 16, 2003Publication date: March 25, 2004Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
-
Publication number: 20030035815Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: ApplicationFiled: June 5, 1995Publication date: February 20, 2003Inventors: BRUCE L. ROGERS, JAY P. MORGENSTERN, JULIAN F. BOND, RICHARD D. GARMAN, JULIA L. GREENSTEIN, MEI-CHANG KUO, MALCOLM MORVILLE
-
Patent number: 6120769Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.Type: GrantFiled: April 28, 1995Date of Patent: September 19, 2000Assignee: ImmuLogic Pharmaceutical CorporationInventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Julian F. Bond
-
Patent number: 6090386Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.Type: GrantFiled: June 6, 1995Date of Patent: July 18, 2000Inventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
-
Patent number: 5547669Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: GrantFiled: December 13, 1991Date of Patent: August 20, 1996Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Malcolm Morville